top of page

SF Healthcare Week: The CEO of Akeso talks about its PD1xVEGF, other bi-specific targets, and her opinion of China's position in the global biotech ecosystem

  • blonca9
  • Jan 14
  • 1 min read

Chairman & CEO Michelle Xia describes the clinical trial that was run comparing the company's PD1xVEGF vs Akeso, development plans outside of lung cancer, other targets (including PD1xCTLA4), and her opinion of the innovation coming out of China.



ree


Join the BiotechTV mailing list

Thanks for subscribing!

Follow BiotechTV

  • Twitter
  • LinkedIn
  • Facebook
  • TikTok
  • Instagram

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

evaluate-logo-png_seeklogo-457165-2_edited.png

Evaluate is a trusted provider of forecasting and commercial intelligence to the pharmaceutical industry. With a combination of gold standard data sources and deep pharma expertise, Evaluate helps clients make the right portfolio decisions to drive growth.

Evaluate's solutions provide a complete, dynamic view of development risk and commercial return across the full clinical lifecycle, underpinned by consensus forecasts to 2032, pipelines, deals and more. A consulting and analytics team is on always hand to help clients address unique clinical and commercial challenges.

bottom of page